Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05933265 · ClinicalTrials.gov registry record · Phase 1

Study of LP-184 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Lantern Pharma.

Recruiting
Registry status
Phase 1
Development phase
175
Enrollment target
9
Study locations

NCT05933265: Recruiting Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Lantern Pharma.

NCT05933265 is a Phase 1 study of Advanced Solid Tumor and NSCLC that is actively recruiting participants, run by Lantern Pharma. The registered enrollment target is 175 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05933265, a Phase 1 study of Advanced Solid Tumor and NSCLC, is actively recruiting participants, sponsored by Lantern Pharma.

RECRUITING
Registry status
Phase 1
Development phase
175 participants
Enrollment target
9
Study locations

Study Summary

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity

Conditions Studied

Advanced Solid Tumor NSCLC Pancreatic Adenocarcinoma Metastatic Solid Tumor GBM TNBC - Triple-Negative Breast Cancer DDR Gene Mutation

Interventions

  • DRUG Olaparib
  • DRUG Spironolactone
  • DRUG LP-184

Study Locations (9)

Arkansas

  • Highlands Oncology Group - Springdale

California

  • Cancer and Blood Specialty Clinic - Los Alamitos

Illinois

  • Northwest Oncology & Hematology - Rolling Meadows

Indiana

  • Indiana University Melvin and Bren Simon Cancer Center - Indianapolis

Kentucky

  • Norton Healthcare, Inc. - Louisville

Maryland

  • John Hopkins - The Sidney Kimmel Comprehensive Cancer Center - Baltimore

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Texas

  • UT Health Science Center San Antonio - San Antonio

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2023-06-09
Est. Completion 2025-09-09
Phase Phase 1
Lantern Pharma

3 total trials

What NCT05933265 shows while recruiting

NCT05933265 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target.

The record links to 7 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Olaparib is the first listed.

NCT05933265 lists 9 locations in 9 states (Arkansas, California, Illinois).

Frequently Asked Questions

What is clinical trial NCT05933265 about?

NCT05933265 is a clinical study titled "Study of LP-184 in Patients With Advanced Solid Tumors". The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of...

What is the current status of trial NCT05933265?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2023-06-09. Estimated completion is 2025-09-09.

What conditions does trial NCT05933265 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, NSCLC, Pancreatic Adenocarcinoma, Metastatic Solid Tumor, GBM.

What interventions are being tested in trial NCT05933265?

The interventions under investigation include: Olaparib (DRUG), Spironolactone (DRUG), LP-184 (DRUG).

Who is sponsoring clinical trial NCT05933265?

This trial is sponsored by Lantern Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05933265 being conducted?

This trial has 9 study locations across Arkansas, California, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05933265's enrollment target sits among peer trials

175 74th of 189 higher than 116 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04722341 · 175 participants · NA

    Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

  • NCT05094037 · 175 participants · NA

    Orthotic Treatment of Diabetic Foot Ulcers

  • NCT05165745 · 175 participants · NA

    Stick2PrEP Cisgender Women and Trans Individuals

  • NCT05312255 · 175 participants · NA

    Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05933265

Source: ClinicalTrials.gov NCT05933265, the US trial registry maintained by the National Library of Medicine. NCT05933265 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.